New CFDs added on cannabis stocks

Forex broker EuropeFX, which is regulated by CySEC, has added four new contracts for difference (CFDs) to its trading platform. The new CFDs give access to EuropeFX clients to the companies operating in the cannabis industry, which is growing daily.

With EuropeFX it is now possible to get shares of bellow companies:

• GW Pharmaceuticals
• AbbieVie Inc
• Insys Therapeutics Inc
• Scotts Miracle-Gro

Marijuana stocks have been a very lucrative opportunity for many investors over the last several months. This caused many retail brokers to step in to meet this demand and profit from it. But many investors, who were defeated by the boom of the cryptocurrency exchange, should be very careful when investing into this asset since many of the insiders think that there’s a chance for marijuana stocks to be the next bubble. We cannot advise if you should invest in it or not, but what we can advise is to compare the forex brokers and carefully choose one to be on the safe side.

Demand for cannabis stocks is growing

It is not surprising that the interest in marijuana both from investors and brokers have risen. It is connected to recent events as many countries have been voting in favor of the legalization of marijuana usage. 2018 has been a remarkable year of two of the big countries the US and Canada.
The United States has made some big improvements for U.S. cannabis operators. At the same time, marijuana companies that are operating in the US have been doing a lot to expand their capacities, make their product line more various and generally to be distinctive among other companies. Meanwhile, the Cannabis Act passed in Canada which has legalized usage of marijuana in the country.

EuropeFX, CEO Guy Illouz, has made comments about these changes and cannabis sector. He stated that the legalization of medical cannabis in the US and passing Cannabis Act in Canada have created a whole new sector for companies to operate in and for the traders to invest in. As Illouz said, many of their clients have expressed huge interest in the cannabis marketplace and as a company, they are dedicated to meeting and exceeding client expectations.

While these companies mentioned above do not produce a mainstream product and are active in the sphere of medical cannabis, they still have to comply with the same regulatory guidelines as other companies on the same exchanges.